Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Gains from Investment Securities (2021 - 2025)

Historic Gains from Investment Securities for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $9.6 million.

  • Amylyx Pharmaceuticals' Gains from Investment Securities rose 1504.37% to $9.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.6 million, marking a year-over-year increase of 1504.37%. This contributed to the annual value of $7.7 million for FY2024, which is 2132.23% down from last year.
  • Per Amylyx Pharmaceuticals' latest filing, its Gains from Investment Securities stood at $9.6 million for Q3 2025, which was up 1504.37% from $9.8 million recorded in Q2 2025.
  • In the past 5 years, Amylyx Pharmaceuticals' Gains from Investment Securities registered a high of $11.7 million during Q1 2023, and its lowest value of -$1.9 million during Q2 2021.
  • For the 5-year period, Amylyx Pharmaceuticals' Gains from Investment Securities averaged around $6.1 million, with its median value being $8.3 million (2024).
  • Per our database at Business Quant, Amylyx Pharmaceuticals' Gains from Investment Securities skyrocketed by 54884.42% in 2022 and then tumbled by 9401.71% in 2024.
  • Amylyx Pharmaceuticals' Gains from Investment Securities (Quarter) stood at $1.7 million in 2021, then surged by 382.35% to $8.2 million in 2022, then crashed by 73.17% to $2.2 million in 2023, then fell by 16.95% to $1.8 million in 2024, then surged by 425.39% to $9.6 million in 2025.
  • Its Gains from Investment Securities was $9.6 million in Q3 2025, compared to $9.8 million in Q2 2025 and $100000.0 in Q1 2025.